The iHealth’s COVID-19/Flu A&B 3-in-1 Antigen Rapid Test delivers results in 15 minutes. Credit: PRNewswire/ iHealth Labs, Inc.

The US Food and Drug Administration (FDA) has granted emergency use authorization (EUA) for iHealth Labs’ new COVID-19/Flu A&B rapid test kit.

Intended to deliver results in 15 minutes, the 3-in-1 test kit is said to be one of the first over-the-counter rapid antigen tests for both Covid-19 and influenzas A and B in the US.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

It is used for self-testing at home and is suitable for individuals aged two and above, with adult assistance required for children between the ages of two and 13 years.

Building on the user-friendly design of iHealth’s standalone at-home Covid test, the new test requires five drops on the test card, a slight increase from the previous three drops.

The lateral flow immunoassay displays results for Covid-19, influenza A, and influenza B.

See Also:

The iHealth COVID-19/Flu A&B Rapid Test is designed for the qualitative detection and differentiation of SARS-CoV-2, influenza A, and influenza B protein antigens.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

iHealth CEO Jack Feng said: “In the face of uncertainty surrounding symptoms such as fever, sneezing, cough, or fatigue and what illness they may be indicative of, our at-home 3-in-1 self-test offers peace of mind for parents who might be worried that their vulnerable young children have Covid-19 or the flu.

“As we did with the stand-alone at-home Covid test during the pandemic, our goal now with this second generation of at-home testing that introduces combination tests such as the 3-in-1, is to evolve with consumer and public healthcare needs to deliver products that address immediate concerns.”

Only those who have respiratory infection symptoms and indications consistent with Covid-19 within the first four days of symptom onset, are eligible for this test.

Last year, iHealth Labs said it manufactured more than 70 million Covid-19 at-home test kits at its facility in Irwindale, California.